Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01399437 · ClinicalTrials.gov registry record

Brain Functions Underlying Visuospatial Attention Deficits in Schizophrenia

A clinical trial, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
64
Enrollment target

NCT01399437: Completed study, sponsored by National Institute on Drug Abuse (NIDA).

NCT01399437 is a clinical trial that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01399437 has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
64 participants
Enrollment target

Study Summary

Background: \- A special brain circuit is important for helping us keeping an eye open for things that are going on around us, even when we are not directly paying attention to them. This circuit seems to work differently in people with schizophrenia than in other people, which may explain specific deficits with broad monitoring observed in people with schizophrenia. Researchers want to compare brain function in people with schizophrenia and healthy volunteers to find out more about how these brain circuits work and affect attention. Objectives: \- To study how the brain performs broad visual monitoring in people with schizophrenia. Eligibility: * Individuals between 18 to 55 years of age who have been diagnosed with schizophrenia. * Healthy volunteers between 18 and 55. Design: * Participants will be screened with physical and psychological exams. They will have a medical history. Tests for drug and alcohol use will also be done. * Participants will have two study visits. The first is a training visit and the second is a scanning visit. * At the training visit, participants will practice computer-based tests of focus, memory, and concentration. They will also answer questions about mood, psychiatric symptoms, and smoking habits. * At the scanning visit, participants will perform the computer-based tasks that they practiced at the training visit. They will have magnetic resonance imaging while they perform these tasks.

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2011-07-03
Est. Completion 2014-12-24

What the finished NCT01399437 record still lists

NCT01399437 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT01399437 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01399437 about?

NCT01399437 is a clinical study titled "Brain Functions Underlying Visuospatial Attention Deficits in Schizophrenia". Background: \- A special brain circuit is important for helping us keeping an eye open for things that are going on around us, even when we are not directly paying attention to them. This circuit seems to work differently in people with schizophrenia than in other people, which may explain specific...

What is the current status of trial NCT01399437?

This trial is currently completed. The enrollment target is 64 participants. The study started on 2011-07-03. Estimated completion is 2014-12-24.

Who is sponsoring clinical trial NCT01399437?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01399437, the US trial registry maintained by the National Library of Medicine. NCT01399437 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.